Test Price
2,800 AED✅ Home Collection Available
LRRC6 Gene Primary Ciliary Dyskinesia Type 19 Genetic Test | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing with dual independent bioinformatics interpretation.
Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM. Standard specimen types include whole blood, extracted DNA, or dried blood spot.
Clinical Guidance: Complementary telephonic post-test result interpretation with a DHA-licensed Consultant Medical Genetics specialist (DHA ID: 9294403).
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
This molecular diagnostic assay detects pathogenic variants in the LRRC6 gene associated with Primary Ciliary Dyskinesia type 19, enabling precise genetic confirmation, carrier detection, and recurrence risk assessment for affected families.
Test Overview & Methodology
The LRRC6 NGS test screens for pathogenic variants causing Primary Ciliary Dyskinesia type 19, a rare autosomal recessive disorder that impairs mucociliary clearance, leading to chronic respiratory infections, sinusitis, bronchiectasis, and possible situs inversus. Our high-coverage next-generation sequencing panel detects single nucleotide variants, small insertions and deletions, and copy number changes with superior analytical sensitivity compared to traditional Sanger sequencing or electron microscopy approaches.
| Feature | Our Test (Premium NGS Diagnostics) | Conventional PCD Work-up |
|---|---|---|
| Analytical Precision | >99.9% sensitivity using unique molecular barcodes and high-coverage NGS | ~85% sensitivity with electron microscopy ciliary ultrastructure and targeted Sanger sequencing |
| Method | Whole LRRC6 gene and flanking intronic regions sequenced on Illumina NovaSeq X Plus with validated bioinformatics pipeline | Electron microscopy of nasal brush biopsy or single-gene Sanger dideoxy sequencing |
| Turnaround Time | 21–28 business days from sample receipt | 6–10 weeks (electron microscopy plus multiple Sanger assays) |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA ID: 9294403): "This genetic test provides a definitive molecular diagnosis for Primary Ciliary Dyskinesia type 19. A positive result must always be correlated with clinical history, nasal nitric oxide levels, and pulmonary function assessments. A negative result does not entirely exclude PCD, as rare deep-intronic or regulatory variants may remain undetected by current sequencing platforms. Pre-test and post-test genetic counselling is strongly recommended to place results within the family context and guide reproductive planning."
Advisory on Medication Continuity
Do not alter or discontinue any prescribed therapies—including bronchodilators, inhaled corticosteroids, or antibiotics—without consulting your treating pulmonologist. This genetic test is a diagnostic adjunct and does not replace acute medical evaluation or ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide an adequate biological sample via standard venipuncture or finger-stick; severe thrombocytopenia or uncorrected bleeding disorder not cleared by the attending physician.
- Red Flag – Seek Immediate Emergency Care: Sudden onset chest pain, high fever above 39°C with productive cough, cyanosis, or respiratory distress. These may indicate acute pneumonia or pneumothorax and require urgent medical attention.
- Post-test Vigilance: If the genetic result confirms PCD, adhere strictly to your pulmonologist’s airway clearance regimen and infection prevention plan to reduce exacerbation risk.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the LRRC6 genetic test and how does it change management?
Identifying a biallelic LRRC6 mutation confirms PCD type 19, enabling early enrollment in specialized pulmonary care, avoidance of unnecessary ear-nose-throat surgeries, and carrier screening for at-risk relatives. A definitive molecular diagnosis guides personalized airway clearance devices, inhaled therapies, and cardiac surveillance in cases of laterality defects.
2. How should I prepare for the test and what sample types are accepted?
No fasting or medication adjustment is required. The laboratory accepts whole blood (3–5 mL in EDTA), pre-extracted DNA (minimum 1 µg), or a dried blood spot on a Whatman FTA card. Completing a genetic counselling session beforehand is recommended to document family history and construct a pedigree of relatives affected by primary ciliary dyskinesia or related ciliopathies.
3. Why choose this test over traditional diagnostic methods like electron microscopy?
Next-generation sequencing detects LRRC6 mutations with 99.9% sensitivity even when ciliary ultrastructure appears normal on biopsy, and avoids invasive nasal brushings. The test also identifies carriers and atypical variants, providing a precise recurrence risk for future pregnancies—all within three to four weeks, substantially faster than multi-step morphological work-ups.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance: DNA Labs UAE fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within UAE jurisdiction. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your results are confidential and shared only with the requesting physician unless explicit written consent is provided.
Clinical & Logistical Metadata
| Test Name | LRRC6 Gene Primary Ciliary Dyskinesia Type 19 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 business days |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA (≥1 µg), or dried blood spot (DBS) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq X Plus with dual independent bioinformatics interpretation |
| ICD-10-CM Code | Q34.8 |
| LOINC Code | 95274-1 |
| DHA Facility License & Laboratory Address | License No: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians